CJC-1295 With DAC
GHRH analog (Drug Affinity Complex)
Week-long GH release.
Half-life
~ 7–8 days (albumin-bound)
Mol. weight
3647.3 g/mol (DAC:GRF)
Sequence
Modified GRF(1-29) + Drug Affinity Complex (albumin-binding) linker
Discussions
0 threads
Overview
A growth hormone-releasing hormone analog modified with a Drug Affinity Complex (DAC) that binds serum albumin, extending the plasma half-life from minutes to roughly 7–8 days and enabling once- or twice-weekly dosing. It is researched for sustained elevation of GH and IGF-1, in contrast to the short-acting no-DAC variant that preserves pulsatile release.
Mechanism of action
CJC-1295 with DAC is a GHRH analog whose DAC moiety covalently attaches to albumin in the bloodstream, protecting it from degradation and extending its half-life to ~7–8 days. By continuously signaling GHRH receptors at the pituitary, it produces a sustained elevation of growth hormone and downstream IGF-1 rather than the discrete pulses of the native hormone. The trade-off is convenience versus physiological fidelity: less frequent dosing, but a less natural GH profile that some researchers believe can attenuate the amplitude of endogenous pulses over time.
Researched benefits
- Sustained GH and IGF-1 elevation
- Once- or twice-weekly dosing
- Studied for body composition and recovery
Considerations
- Less pulsatile, less physiological GH profile
- May attenuate natural pulse amplitude
- Quality sourcing critical; professional guidance required
Key Academic Literature & Studies
Search more in PubMedPeer-reviewed citations and clinical trials evaluating CJC-1295 With DAC in scientific literature.
Query PubMed for recent peer-reviewed preclinical and clinical publications on CJC-1295 With DAC:
View CJC-1295 With DAC index on PubMed (NCBI)